Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy
10.4062/biomolther.2023.149
- Author:
Bisan El DAKKAK
1
;
Jalal TANEERA
;
Waseem EL-HUNEIDI
;
Eman ABU-GHARBIEH
;
Rifat HAMOUDI
;
Mohammad H. SEMREEN
;
Nelson C. SOARES
;
Eman Y. ABU-RISH
;
Mahmoud Y. ALKAWAREEK
;
Alaaldin M. ALKILANY
;
Yasser BUSTANJI
Author Information
1. Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates
- Publication Type:Review
- From:Biomolecules & Therapeutics
2024;32(3):267-280
- CountryRepublic of Korea
- Language:English
-
Abstract:
Apoptosis, programmed cell death pathway, is a vital physiological mechanism that ensures cellular homeostasis and overall cellular well-being. In the context of cancer, where evasion of apoptosis is a hallmark, the overexpression of anti-apoptotic proteins like Bcl2, Bcl-xL and Mcl-1 has been documented. Consequently, these proteins have emerged as promising targets for therapeutic interventions. The BCL-2 protein family is central to apoptosis and plays a significant importance in determining cellular fate serving as a critical determinant in this biological process. This review offers a comprehensive exploration of the BCL-2 protein family, emphasizing its dual nature. Specifically, certain members of this family promote cell survival (known as anti-apoptotic proteins), while others are involved in facilitating cell death (referred to as pro-apoptotic and BH3-only proteins). The potential of directly targeting these proteins is examined, particularly due to their involvement in conferring resistance to traditional cancer therapies.The effectiveness of such targeting strategies is also discussed, considering the tumor’s propensity for anti-apoptotic pathways.Furthermore, the review highlights emerging research on combination therapies, where BCL-2 inhibitors are used synergistically with other treatments to enhance therapeutic outcomes. By understanding and manipulating the BCL-2 family and its associated pathways, we open doors to innovative and more effective cancer treatments, offering hope for resistant and aggressive cases.
